RecruitingPhase 2NCT06668792

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Subjects With Relapsed/Refractory Multiple Myeloma

Sponsor

Biocad

Enrollment

100 participants

Start Date

Dec 26, 2024

Study Type

INTERVENTIONAL

Conditions

Relapsed/Refractory Multiple Myeloma

Summary

The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new treatment called BCD-248 for people with multiple myeloma (a blood cancer affecting plasma cells) whose cancer has come back or stopped responding after at least two prior treatment regimens. It is an open-label study, meaning both participants and doctors know what treatment is being given. **You may be eligible if...** - You are 18 or older with confirmed multiple myeloma - You have received at least 2 prior treatment lines, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 therapy - Your disease progressed during or after your last treatment - You had at least a partial response to at least one prior treatment - You are in acceptable health (ECOG 0–2) **You may NOT be eligible if...** - You previously received anti-BCMA or anti-CD3 therapies - You had a stem cell transplant within the past 12 weeks (autologous) or any time (allogeneic) - You have serious heart, liver, kidney, or lung problems - You have had another cancer within the last 5 years (with some exceptions) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBCD-248

subcutaneously

Locations(20)

SBHI of the Kaliningrad region "Central City Clinical Hospital"

Kaliningrad, Russia

SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigala"

Kazan', Russia

FSBI of science "Kirov research Institute of Hematology and blood transfusion of the Federal medical and biological Agency"

Kirov, Russia

Regional Government-Owned Publicly Funded Healthcare Institution "Regional Clinical Hospital"

Krasnoyarsk, Russia

Branch of the limited liability company "Hadassah Medical LTD"

Moscow, Russia

City Clinical Hospital №52 of the Department of Health of the City of Moscow

Moscow, Russia

FSBI "National Medical Research Center of Oncology named after N. N. Blokhin" of the Ministry of Health of the Russian Federation

Moscow, Russia

JSC "Medsi Group of Companies"

Moscow, Russia

SBI of health care of the city of Moscow city clinical hospital named after S. P. Botkin of the Department of health of the City of Moscow

Moscow, Russia

State budgetary healthcare Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M. F. Vladimirsky"

Moscow, Russia

Federal State Budgetary Institution "National Medical Research Center for Radiology" of the Ministry of Health of the Russian Federation

Obninsk, Russia

SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov"

Petrozavodsk, Russia

FSBI "Almazov National Medical Research Centre" of the Ministry of Health of the Russian Federation

Saint Petersburg, Russia

FSBEI of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation

Samara, Russia

FSBEI HE "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of Russia

Saratov, Russia

Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Smolensk"

Smolensk, Russia

State Budgetary Healthcare Institution "Oncological Dispensary No.2" of the Ministry of Health of the Krasnodar Region

Sochi, Russia

Public institution "Komi Republican cancer clinic"

Syktyvkar, Russia

FSBEI of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation

Ufa, Russia

State budgetary healthcare institution of the Sverdlovsk region "Sverdlovsk regional clinical hospital №1"

Yekaterinburg, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06668792

Related Trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT0497360583 locations

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT0516058487 locations

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT066692477 locations

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT0586201232 locations

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT0585023436 locations